It's more important than ever before for your elected officials to hear from you - don't miss your chance to turn Capitol ...

Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...

In a new study, researchers examined herbal supplements with immune-activating properties that could trigger or worsen ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...

Lupus erythematosus panniculitis (LEP) is one of the less common types of lupus, which causes painful lesions under the skin. Lupus is a chronic autoimmune disease affecting about 1.5 million people ...

Systemic Lupus Erythematosus is one of the most complex autoimmune diseases seen in modern medicine, affecting multiple organs and presenting differently from one patient to another. Often referred to ...

The market opportunities for SLE and LN lie in developing targeted therapies, guided by an understanding of epidemiological trends across major markets. Focus on age, sex, and severity can enhance ...

Please provide your email address to receive an email when new articles are posted on . Early mycophenolate mofetil in newly diagnosed SLE led to fewer severe flares and lower incidence of lupus ...

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US ...

AN understanding of the interrelations of pregnancy and systemic lupus erythematosus is of considerable clinical importance, particularly since the disease occurs most frequently in women during the ...